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ABSTRACT
Introduction: Adolescents with inflammatory bowel
disease (IBD) show a higher prevalence of depression
and anxiety, compared to youth with other chronic
diseases. The inflammation-depression hypothesis
might explain this association, and implies that treating
depression can decrease intestinal inflammation and
improve disease course. The present multicentre
randomised controlled trial aims to test the
effectiveness of an IBD-specific cognitive–behavioural
therapy (CBT) protocol in reducing symptoms of
subclinical depression and anxiety, while improving
quality of life and disease course in adolescents with
IBD.
Methods and analysis: Adolescents with IBD (10–
20 years) from 7 hospitals undergo screening (online
questionnaires) for symptoms of depression and
anxiety. Those with elevated scores of depression
(Child Depression Inventory (CDI) ≥13 or Beck
Depression Inventory (BDI) II ≥14) and/or anxiety
(Screen for Child Anxiety Related Disorders: boys ≥26,
girls ≥30) receive a psychiatric interview. Patients
meeting criteria for depressive/anxiety disorders are
referred for psychotherapy outside the trial. Patients
with elevated (subclinical) symptoms are randomly
assigned to medical care-as-usual (CAU; n=50) or CAU
plus IBD-specific CBT (n=50). Main outcomes: (1)
reduction in depressive and/or anxiety symptoms after
3 months and (2) sustained remission for 12 months.
Secondary outcomes: quality of life, psychosocial
functioning, treatment adherence. In addition, we will
assess inflammatory cytokines in peripheral blood
mononuclear cells and whole blood RNA expression
profiles. For analysis, multilevel linear models and
generalised estimating equations will be used.
Ethics and dissemination: The Medical Ethics
Committee of the Erasmus MC approved this study. If
we prove that this CBT improves emotional well-being
as well as disease course, implementation is
recommended.
Trial registration number: NCT02265588.
BACKGROUND
Inﬂammatory bowel disease (IBD; Crohn’s
disease (CD) and ulcerative colitis (UC)) is a
chronic relapsing inﬂammatory disorder of
the intestine, with increasing incidence and
prevalence worldwide.1 Patients have abdom-
inal pain, bloody diarrhoea, often accompan-
ied by systemic symptoms such as lack of
appetite, weight loss and fatigue. IBD has a
ﬂuctuating course, with relapses (increased
disease activity) and periods of clinical remis-
sion. In up to 25% of patients, IBD manifests
during late childhood and adolescence.2–4
Adolescence is a challenging life phase, with
signiﬁcant psychological, physical and social
changes. Having IBD during adolescence is a
threat to healthy psychosocial development,
making transition to adulthood more
difﬁcult.
Adolescent patients with IBD frequently
experience psychological and social pro-
blems.5 They often have low self-esteem and
report stress concerning their disease and
future.6 In addition, their quality of life is
reduced2 7 8 due to the unpredictable course
of disease, embarrassing symptoms, frequent
hospital visits or admissions and (side effects
of) medical treatment. Furthermore, the pos-
sible extra intestinal manifestations (eg,
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primary sclerosing cholangitis, arthritis), complications
(eg, strictures) and surgical treatments (eg, resections)
reduce quality of life signiﬁcantly.2 8–12
Depressive symptoms are common, and occur in 20–
40% of adolescents with IBD.13–18 Anxiety, reported in 30–
50% of adolescents with IBD, is even more common.7 19
In many young patients, symptoms of depression and
anxiety occur together.20 21 Not surprisingly, early onset of
mental health problems can predict poor long-term
medical and psychological outcomes.22–24
Taken together, it is clear that psychological problems
are often found in young patients with IBD. The inﬂam-
mation–depression hypothesis has been proposed to
explain the association between psychological problems
and IBD, and implies that treating emotional symptoms
can decrease intestinal inﬂammation, and thus, improve
disease course.25 This hypothesis will be discussed in
detail later in this paper.
Factors associated with depression and anxiety in IBD
Medical, psychological and family factors are associated
with depression and anxiety in IBD and can inﬂuence
the effectiveness of treatment of emotional problems in
IBD. Known medical factors are: being recently diag-
nosed with IBD,26 a diagnosis of CD (vs UC),27 a history
of surgery,27 28 active disease,26–32 non-adherence to
therapy31 and IBS (like) symptoms.33 Psychological
factors are: high levels of perceived stress,26 negative cog-
nitive coping,15 low self-esteem8 34 and sleep disturb-
ance.32 Family factors are: parental stress,35 36 low
socioeconomic status,26 27 31 stressful life events37 and
unhealthy family functioning.10 34 37 In paediatric
patients, active disease15 18 19 38 39 and low socio-
economic status15 are associated with depression and/or
anxiety.
In the opposite direction, emotional problems have
also been shown to inﬂuence disease activity.
Psychological stress can trigger a relapse in IBD30 40–44
and lead to a more difﬁcult-to-treat (refractory)
disease.30 Moreover, emotional problems decrease the
ability to cope with physical symptoms, increase the sen-
sitivity to abdominal pain,45 increase medical service use
and decrease therapy adherence.16 19 29 46 47
Altogether, these ﬁndings emphasise the existence of
a bidirectional relationship between emotional problems
and disease activity in patients with IBD. We therefore
expect that early recognition and treatment of emo-
tional problems is necessary to improve both mental
health and the clinical course of disease.
Inflammation–depression hypothesis
The ‘inﬂammation–depression hypothesis’ or ‘brain–gut
hypothesis’ proposes that intestinal inﬂammation, by
means of increased production of proinﬂammatory cyto-
kines (eg, tumour necrosis factor α (TNF-α)), is known
to directly and indirectly affect the brain and thereby
increase symptoms of depression.48 It is also suggested
that psychological stress can increase depressive symp-
toms by increasing inﬂammation.25 48 49
Most evidence for this hypothesis comes from animal
studies in which experimental (psychological) stress has
shown to induce and reactivate inﬂammation in colitis
models.44 It is suggested that these stress-induced altera-
tions in inﬂammation are mediated through changes in
hypothalamic–pituitary–adrenal axis function, and
alterations in bacterial mucosal interactions.25 44 50–52
Similarly, human studies also show the proinﬂammatory
effect of experimental25 50 and (early) life stress,52 and
show elevated levels of inﬂammatory markers in
depressed patients.49 53–56
There are few paediatric IBD studies examining the
relationship between inﬂammation and depression.48
Furthermore, the brain–gut hypothesis mainly focuses on
depression, the relation between inﬂammation and
anxiety has been studied less extensively.57 Reviews by
Hou and Baldwin58 and Salim et al59 show the existing evi-
dence in animal models linking inﬂammation with
anxiety. In humans, a chronic anxiety state has been
shown to negatively affect immune function, and several
studies report a positive correlation between anxiety and
increased inﬂammatory markers.57–60 To the best of our
knowledge, little is known about the association between
anxiety and inﬂammation in IBD. The present study will
contribute to more understanding of this association.19 31
CBT for adolescents with IBD
From all different psychotherapies, cognitive–behav-
ioural therapy (CBT) is the most evidence-based psycho-
therapy to reduce symptoms of anxiety and
depression.12 61 62
For adolescents with IBD, Szigethy et al63 developed a
disease-speciﬁc CBT programme called PASCET-PI
(Primary and Secondary Control Enhancement Training
—Physical Illness) (see Intervention section). They per-
formed a randomised controlled trial (RCT) (2007) in
adolescents with IBD and subclinical depression (total
N=41). A 40% reduction in depressive severity in the
PASCET-PI group was found compared to the control
group, receiving care-as-usual (CAU).17 These positive
effects were maintained 1 year after treatment.23
However, anxiety was not addressed. Only a few paediat-
ric studies have integrated the clinical course of disease
or disease activity as an outcome parameter. Szigethy
et al64 compared the effect of two different psychothera-
pies in paediatric patients with IBD with (sub)clinical
depression and found that both therapies had a signiﬁ-
cant impact in improving depression, while CBT was
associated with a greater reduction in disease activity.
Reigada et al65 showed in a CBT-pilot with nine (paediat-
ric) patients and only comorbid anxiety, that 90% no
longer had an anxiety disorder and half the patients had
a reduction in IBD severity.
Although the aforementioned studies showed promis-
ing results, larger scale randomised studies are necessary
to evaluate the longitudinal effect of CBT in paediatric
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IBD, and to identify potential moderators of CBT
success. To the best of our knowledge, at present, there
are no RCTs assessing simultaneously the effect of CBT
on the two psychological outcomes (symptoms of
depression or anxiety) and the clinical course of disease
in adolescents with IBD.
Aim and hypothesis
The aim of the present study is to test the effectiveness
of the disease-speciﬁc CBT programme (PASCET-PI) in
reducing symptoms of depression and anxiety in adoles-
cents with IBD in order to improve quality of life and to
improve the clinical course of disease. We hypothesise
that the PASCET-PI will reduce symptoms of both
depression and anxiety, improve quality of life, reduce
intestinal inﬂammation and will promote sustained clin-
ical remission.
METHODS AND DESIGN
Study design
This study is a prospective, multicentre, RCT, with base-
line screening (T0) and three follow-up assessments
(T1–T3). At baseline, adolescents (aged 10–20 years)
with IBD are screened for symptoms of depression and
anxiety by means of an online questionnaire. Patients
with elevated (subclinical) symptoms of depression and/
or anxiety, but no clinical disorder, are randomised into
two conditions. The control condition entails standard
medical CAU; psychological care is not standard in the
Dutch medical care system. Patients in the experimental
condition receive standard medical care plus the disease-
speciﬁc CBT (PASCET-PI). Patients are recruited from
two academic hospitals and ﬁve community hospitals in
the South-West region of the Netherlandsi. The design
of this study is following the CONSORT guidelines
for RCTs.
Inclusion and exclusion criteria
Inclusion criteria are: (1) patients between 10 and
20 years of age with diagnosed IBD and (2) informed
consent provided by patients and (if applicable) parents.
Exclusion criteria are: (1) mental retardation (parent
report); (2) current psychopharmacological treatment
for depression or anxiety; (3) current psychological
treatment; (4) having received manualised CBT in the
past year (at least 8 sessions); (5) insufﬁcient mastery of
the Dutch language; (6) diagnosed bipolar disorder,
schizophrenia/psychotic disorder, autism spectrum dis-
orders, obsessive-compulsive disorder, post-traumatic,
acute stress-disorder or substance use disorder; (7)
selective mutism (physician reported) and (8) already
participating in an intervention study.
Recruitment and procedure
See ﬁgure 1 for an overview of the procedure. The treat-
ing (paediatric) gastroenterologist, nurse practitioner or
physician assistant informs eligible patients about this
study and hands out the written patient information.
Parents are asked for informed consent if patients are
younger than 18 years; if patients aged 18 years or older
still live in their parents’ house, participation of parents
is optional. After having given informed consent,
patients (and parents) receive an e-mail with online
questionnaires (table 1). If this screening shows self-
reported subclinical symptoms of depression and/or
anxiety, a patient is selected for further participation in
the study. The Dutch versions of the Child Depression
Inventory (CDI; ages 10–17 years),66 Beck Depression
Inventory (BDI-II; ages 18–20 years),67 are used to assess
Figure 1 Flow chart study design (ADIS-C/P, Anxiety
Disorders Interview Schedule—Child and Parent Version;
ADRS, Adolescent Depression Rating Scale; BDI-II, Beck
Depression Inventory—Second Edition; CDI, Child
Depression Inventory; CDRS-R, Child Depression Rating
Scale—Revised; PARS, Pediatric Anxiety Rating Scale;
SCARED, Screen for Child Anxiety Related Emotional
Disorders).
iErasmus MC(-Sophia), Leiden University Medical Centre (LUMC),
Haga ( Juliana Children’s) Hospital, Reinier de Graaf Gasthuis,
Maasstad Hospital, Amphia Hospital, and Albert Schweitzer Hospital.
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Table 1 Outcomes, covariates, instruments and informants at each time point
Measurements
T0
baseline
T1
3 months
T2
6 months
T3
12 months
Main psychological outcomes
Change in symptoms of depression
CDI (10–17 year) Pt Pt Pt Pt
BDI-II (18–20 year) Pt Pt Pt Pt
ADIS-C/P Pt, Pr Pt, Pr Pt, Pr Pt, Pr
CDRS-R (10–12 year) Ps Ps Ps Ps
ADRS (13–20 year) Ps Ps Ps Ps
Change in symptoms of anxiety
SCARED Pt Pt Pt Pt
ADIS-C/P Pt, Pr Pt, Pr Pt, Pr Pt, Pr
PARS Ps Ps Ps Ps
Main medical outcome
Sustained remission M
Secondary psychological outcomes
(Change in) Quality of life
TACQOL (10–15 year)76 Pt Pt Pt Pt
TAAQOL (16–20 year)77 Pt Pt Pt Pt
IMPACT-III78 Pt Pt Pt Pt
(Change in) Psychosocial functioning
SSRS79 Pt Pt Pt Pt
YSR (10–17 year)80 Pt Pt Pt Pt
ASR (18–20 year)81 Pt Pt Pt Pt
Secondary medical outcomes
(Change in) Disease activity
PUCAI (ulcerative colitis) M M M M
PCDAI (Crohn’s disease) M M M M
Physician Global Assessment46 M M M M
Inflammatory markers
CRP Pt Pt Pt Pt
ESR Pt Pt Pt Pt
Faecal calprotectin Pt Pt Pt Pt
Use of IBD medication
Steroids, anti-TNF blockers, immunomodulators M M M M
Necessity of surgical intervention M M M M
Psychological covariates
Demographic factors
Rotterdam’s quality of life interview82 Pr
Illness perception
B-IPQ83 Pt Pt Pt Pt
Cognitive coping styles
CERQ84 Pt Pt Pt Pt
Quality of sleep
SSR85 Pt, Pr Pt, Pr Pt, Pr Pt, Pr
Parental anxiety and depression
DASS-2186 Pr
Life events
Stress scale thermometer87 Pt, Pr Pt, Pr Pt, Pr Pt, Pr
Life events questionnaire from CERQ Pt Pt
Family functioning
FAD-GF88 Pr Pr Pr Pr
Medical covariates
Disease phenotypes
Medical file analysis using Paris Classification M
Treatment strategy
Report of treating physician/medical file analysis M M M M
IBS-like symptoms
Questionnaire based on Rome III criteria IBS M M M M
Continued
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depressive symptoms, whereas the Screen for Child
Anxiety Related Disorders (SCARED; ages 10–20)68 is
used to assess anxiety symptoms. Subclinical depressive
symptoms are deﬁned as a score equal to or above the
cut-off on the CDI (13)66 or the BDI-II (14).67
Subclinical anxiety symptoms are deﬁned as: (1) a score
equal to or above the cut-off on the total scale of the
SCARED (26 for boys, 30 for girls) or (2) a score equal
to or above the cut-off (8) on one of the subscales.69
Next, in patients with these subclinical symptoms, the
Anxiety Disorders Interview Schedule—Child and
Parent Version (ADIS-C/P)70 71 is administered by a
research psychologist by telephone. Thereafter, the
severity of depressive and/or anxiety symptoms is rated
by the research psychologist using the Child Depression
Rating Scale—Revised (CDRS-R; ages 10–12 years),72 the
Adolescent Depression Rating Scale (ADRS; ages 13–20
years)73 and the Pediatric Anxiety Rating Scale (PARS;
ages 10–20 years).74 Patients are excluded for randomisa-
tion if they meet criteria for a clinical depressive or
anxiety disorder on the ADIS-C/P and score equal to or
above the clinical cut-off on the CDRS (40),75 ADRS
(20)73 or PARS (18).74 Instead, these patients are
referred for attuned psychological treatment, since it
would be unethical to randomise them. For patients
with subclinical depression and/or anxiety, the medical
researcher performs the randomisation and arranges
the medical baseline assessment.
All patients included in our study are well phenotyped
with regard to duration and severity of disease, age at
diagnosis, growth and pubertal development, clinical
course of disease, number and type of surgical interven-
tions and hospitalisations. The Paris classiﬁcation is col-
lected at diagnosis and from the most recent endoscopy,
to see if extension of disease has occurred.
Randomisation and blinding
Patients are allocated to PASCET-PI or CAU group by
means of computer-based, block randomisation, strati-
ﬁed per centre. Sealed envelopes sequentially numbered
are provided by the Department of Biostatistics of the
Erasmus Medical Center. Participants assigned to the
treatment group start treatment within a maximum of
4 weeks.
To prevent bias in the assessment, the research psych-
ologist completing the diagnostic interviews at T0–T3 is
blinded for the outcome of randomisation. In addition,
physicians assessing the patient’s disease activity are
blinded. The patients and therapists are asked not to
discuss the psychotherapy with the treating physician.
Unblinding takes place if patients are excluded from
the study (either by withdrawal or an acute need for
care).
Intervention
The PASCET-PI focuses on behavioural activation, cogni-
tive restructuring and problem-solving skills to change
maladaptive behaviours, cognitions and coping strat-
egies.61 Although originally designed to treat depression,
most of the components of PASCET-PI are common for
all CBT protocols, and have much overlap with compo-
nents of CBT protocols speciﬁcally designed for anxiety
(except for a fear hierarchy). Therefore, PASCET-PI can
also be properly used for anxiety. Disease-speciﬁc com-
ponents encompass the illness narrative (ie, perceptions
and experience of having IBD), therapy for pain and
immune functioning, disease-speciﬁc psychoeducation,
social skills training and emphasis on IBD-related cogni-
tions and behaviours. Parents are provided with psychoe-
ducation about being a CBT-coach helping their child
coping with IBD.17 89
The PASCET-PI consists of 10 weekly sessions, deliv-
ered in 3 months (table 2). Six sessions are face to face
(1 h), and four sessions are telephone sessions (30 min).
Three parental sessions are held at the beginning,
middle and end of treatment. For adult patients
(≥18 years) who still live with their parents, this is
recommended but voluntarily. Adult patients who do
not live with their parents, participate without their
parents. Thereafter, three 30 min booster sessions (one
Table 1 Continued
Measurements
T0
baseline
T1
3 months
T2
6 months
T3
12 months
RNA expression profiles
Blood sample M M
Cytokine levels in plasma and peripheral blood mononuclear cells (PMBCs)
Blood sample M M
M, medical file/(paediatric) gastroenterologist; Pr, parent report; Ps, psychologist; Pt, patient (self-report).
ADIS-C/P, Anxiety Disorders Interview Schedule—Child and Parent Version; ADRS, Adolescent Depression Rating Scale; ASR, Adult
Self-Report; BDI-II, Beck Depression Inventory—Second Edition; B-IPQ, Brief—Illness Perception Questionnaire; CDI, Child Depression
Inventory; CDRS-R, Child Depression Rating Scale—Revised; CERQ, Cognitive Emotion Regulation Questionnaire; CRP, C reactive protein;
DASS-21, Depression, Anxiety and Stress Scale—21-item version; ESR, erythrocyte sedimentation rate; FAD-GF, Family Assessment Device
—General Functioning scale; IBD, inflammatory bowel disease; IBS, Irritable Bowel Syndrome; PARS, Pediatric Anxiety Rating Scale; PCDAI,
Pediatric Crohn’s Disease Activity Index; PMBC, peripheral blood mononuclear cells; PUCAI, Pediatric Ulcerative Colitis Activity Index;
SCARED, Screen for Child Anxiety Related Emotional Disorders; SSR, Sleep Self-Report; SSRS, Social Skills Rating System; TAAQOL,
TNO-AZL questionnaire for Adult health-related Quality Of Life; TACQOL, TNO-AZL questionnaire for Children’s health-related Quality Of Life;
TNF, tumour necrosis factor; YSR, Youth Self-Report.
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per month) are provided by telephone. For the current
study, the original PASCET-PI was translated into the
Dutch language. During this study, patients will receive
medical care according to the current guidelines.
Psychological interventions, other than the PASCET-PI
for the intervention group, are not allowed.
Training and protocol adherence
Before providing the PASCET-PI, all licensed (health-
care) psychologists had followed a PASCET-PI training
(developed and given by EMS). To prevent protocol
drifting they receive monthly PASCET-PI supervision by
a senior clinical psychologist. All treatment sessions are
audiotaped, and a random 20% is rated by independent
raters (senior clinical psychologist and master’s
Psychology students) using the PASCET-PI Protocol
Adherence Checklist (PPAC).63
Outcome measures
In table 1, an overview of all variables and instruments
at each time point is provided, with informants speciﬁed.
All the psychological questionnaires used are (inter)
nationally validated instruments, for which psychometric
properties have been established in the Netherlands.
Owing to the lack of space, instruments for the main
psychological and medical outcomes are described in
detail below. Instruments for secondary outcomes and
covariates are mentioned only. Covariates will be ana-
lysed as either confounder, mediator or moderator.
Main psychological outcome measures: changes in
symptoms of depression and anxiety
Changes in symptoms of depression are assessed by the
CDI and the BDI-II (to cover the complete age range).
The CDI (used for ages 10–17 years) is a 27-item self-
report scale (response categories 0–2: total score 0–54).
It has excellent reliability (Cronbach’s α >0.85), and
moderate to good validity.66 The BDI-II (used for ages
18–20 years) is a 21-item self-report scale (response cat-
egories 0–3: total score 0–63). The BDI-II has excellent
reliability (Cronbach’s α >0.85) and good to excellent
validity.67 In addition (changes in) the severity of the
depressive symptoms will be rated with the CDRS-R or
the ADRS. The CDRS-R (used for ages 10–12 years) is
one of the most used rating scales for depression in chil-
dren.72 The ADRS (used for ages 13–20 years) is devel-
oped speciﬁcally for adolescent depression.73 Changes
in symptoms of depression are analysed using Z-scores of
CDI and BDI-II, and CDRS-R and ADRS.
Changes in symptoms of anxiety are assessed by the
SCARED (used for ages 10–20 years), a 69-item screen-
ing instrument (response categories 0–2: total score 0–
138) containing ﬁve subscales: general anxiety disorder,
separation anxiety disorder, speciﬁc phobia, panic dis-
order and social phobia. Cronbach’s α in the normative
sample is 0.92 for the total score and between 0.66 and
0.87 for the subscales. Satisfactory concurrent validity
has been shown.68 In addition, changes in the severity of
anxiety symptoms will be rated with the PARS,74 for
which a high internal consistency has been reported.75
For both depression and anxiety, the semistructured
interview ADIS-C/P (child and parent version) is admi-
nistered. This diagnostic interview assesses diagnoses of
depressive or anxiety disorders. Diagnostic and Statistical
Table 2 Outline of the PASCET-PI61
Session
number Content of session
Session 1
Live
Introduction of ACT and THINK model and
PASCET-PI, build alliance,
psychoeducation about IBD and
depression or anxiety, illness narrative
Session 2
Live
Mood monitoring, explaining link between
feelings, thoughts and behaviours,
discussing feeling good and feeling bad,
problem-solving
Session 3
By telephone
Link between behaviour and feelings:
Activities to feel better
Session 4
Live
Be Calm and confident: relaxation
exercises
Session 5
Live
Be calm and Confident: positive self vs
negative self, training social skills
Session 6
By telephone
Talents: developing talents and skills
makes you feel better
Session 7
Live
Social problem solving, discussing the
ACT skills and introduction of the THINK
skills with discussing negative thoughts
(Think positive)
Session 8
By telephone
Help from a friend, Identify the ‘Silver
Lining’ and No replaying bad thoughts
Session 9
By telephone
Keep trying—don’t give up, making
several plans to use the ACT and THINK
skills
Session 10
Live
Quiz on ACT and THINK model,
discussing use of ACT and THINK skills in
the future, updating illness narrative
Booster 1
By telephone
Several plans to use the ACT and THINK
skills, updating illness narrative,
personalising ACT and THINK skills
Booster 2
By telephone
Several plans to use the ACT and THINK
skills, updating illness narrative,
personalising ACT and THINK skills
Booster 3
By telephone
Several plans to use the ACT and THINK
skills, updating illness narrative,
personalising ACT and THINK skills
Family 1
Live
Parental view on IBD, family situation,
psychoeducation about IBD and
depression or anxiety, introduction of ACT
and THINK model and PASCET-PI
Family 2
Live
Parental view on progress, the ACT and
THINK skills that are most effective for
patient, expressing emotions within family,
family communication, family stress game
Family 3
Live
Parental view on progress, family
communication, parental depression or
anxiety
IBD, inflammatory bowel disease; PASCET-PI, Primary and
Secondary Control Enhancement Training—Physical Illness.
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Manual of Mental Disorders (DSM) IV symptoms are
reviewed as either present (‘Yes’) or absent (‘No’).70 71
Main medical outcome measure: sustained remission at
12 months
Sustained remission of IBD (absence of clinical relapse)
is continued clinical remission with no relapses, without
the need to escalate treatment, use of new induction
treatment (except for the ﬁrst 8 weeks after baseline),
hospitalise or perform bowel surgery during the ﬁrst
12 months. In case of active disease at the time of enrol-
ment, sustained remission at 12 months means contin-
ued remission after 8 weeks of induction treatment
starting at baseline. The PCDAI and the PUCAI are used
to score disease activity, and to score remission or
relapse. The PCDAI (for CD) is a validated, multi-item,
physician-reported measure that comprises items on
history (abdominal pain, stools, activity level), physical
examination, height and weight, as well as laboratory
parameters. Scores range from 0 to 100, with higher
scores representing more active disease.90 91 The PUCAI
is a clinical index on disease activity for UC, scored by
the physician, which has been validated in multiple
international drug studies and comprises items on
abdominal pain, rectal bleeding, stool frequency and
consistency and activity level. Scores range from 0 to 85,
with higher scores representing more active disease.92
For patients with CD and UC, remission is deﬁned as
PCDAI <10 and PUCAI <10, respectively. For CD, relapse
is deﬁned as PCDAI >30 or an increase of >15 points
and intensiﬁcation of medical treatment. For UC,
relapse is deﬁned as PUCAI >34 or an increase of ≥20
points for UC and intensiﬁcation of medical
treatment.90 92 93
Secondary outcomes
Secondary psychological outcomes are IBD-related
quality of life and social functioning.
Secondary medical outcomes are disease activity,
inﬂammatory markers in blood (C reactive protein) and
stool (calprotectin), use of IBD medication and necessity
of surgery (see table 1).
Psychological and medical covariates
Several factors associated with depression and anxiety in
IBD (eg, IBS-like symptoms, cognitive coping, parental
stress) will be assessed because they can confound,
mediate or moderate the effect of CBT on medical and
psychological outcomes. Psychological covariates
assessed are: illness perception, cognitive coping, quality
of sleep, parental anxiety and/or depression, stressful
life events, family functioning, and demographic factors.
Medical covariates encompass: disease phenotype,
treatment strategy, disease activity, and IBS-like symp-
toms. Blood samples for immunological analysis will be
drawn at baseline and after 3 months. For cytokine ana-
lysis, one EDTA tube (10 mL) will be drawn. PBMCs will
be isolated and the plasma stored at −80°C. Serum
levels of proinﬂammatory cytokines (TNF-α, IL-1, IL-1β,
IL-6, IL-8) will be assessed in plasma and supernatant of
PBMCs in culture using, respectively, Cytokine Bead
Analysis or ELISA. Furthermore, intracellular ﬂow cyto-
metry will be performed on in vitro-stimulated PBMCs.
For the RNA expression analysis, 2.5 mL venous blood
will be collected in PAXgene tubes (PreAnalytiX) and
stored at −20°C until RNA extraction. Total cellular
RNA will be extracted using the PAXgeneTM blood
RNA kit (Qiagen) according to the manufacturer’s
protocol. Gene expression proﬁles of proinﬂammatory
and anti-inﬂammatory genes in peripheral blood leuco-
cytes will be assessed by Affymetrix U133 2.0 plus
GeneChips.
Data collection: follow-up assessments
Follow-up assessments take place at similar moments in
the CBT and CAU group: 3 (T1), 6 (T2) and 12 (T3)
months after randomisation. Each follow-up assessment
consists of a regular medical visit and a psychological
assessment (online questionnaires and diagnostic psychi-
atric interview) for the patient and, if applicable,
parents. Patients with a clinical depressive or anxiety dis-
order (according to the same criteria as at baseline), or
with an urgent need of psychological help, are excluded.
To ensure participation throughout the study, patients
receive a small reward after completing the last follow-up
assessment.
Withdrawal
Patients can withdraw from the study without any conse-
quences at any time for any reason. Those who withdraw
are asked to complete the follow-up assessments.
Sample size
The target population is a group of approximately 350
patients with IBD aged 10–20 years. Basing on our previ-
ous studies concerning psychological problems in physic-
ally ill adolescents, the expected response rate will be
above 80%,94 which corresponds with ±280 patients.
Basing on literature, around 40% of adolescents with
IBD will suffer from increased symptoms of depression
or anxiety. Of those patients 10% will experience clinical
depression or anxiety. Of the remaining ±100 patients,
50 patients will be randomised to the treatment condi-
tion (CBT and CAU) and 50 to CAU. Sample size is
based on two-tailed tests with size of α=0.05 using a
repeated measures design with estimated correlation
between time points of 0.6. For the effect of CBT on
symptoms of depression, small-effect to medium-effect
sizes are expected (Cohen’s d >0.3),95 96 for the effect
on symptoms of anxiety medium-effect to large-effect
sizes are expected (Cohen’s d >0.6).97 98 For the effect
of CBT on sustainment of remission (no clinical
relapse), a medium-effect size is expected (ω=0.3).
Basing on clinical experience in our hospital, in the
CAU group, 40% of patients will have sustained remis-
sion during 12 months. We hypothesise that 70% of
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patients will have sustained remission in the treatment
group, reﬂecting a medium-effect size. Using the target
population of N=100 and the estimated effects on
depression, anxiety and sustainment of remission, we
will have sufﬁcient power (>0.85).
Statistical analyses
The main analyses will be conducted using an
intention-to-treat approach. Where appropriate, second-
ary analysis will be conducted using a per-protocol basis.
To test the effectiveness of the PASCET-PI, we will
compare the CBT group with the CAU group on (1)
change in symptoms of depression and anxiety and (2)
sustained remission (absence of clinical relapse). For (1)
multilevel linear models will be used, for (2) a general-
ised estimating equation (GEE) approach will be used.
Covariates (eg, illness perception, cognitive coping,
disease phenotypes, medical treatment strategy, inﬂam-
matory markers) will be included into the multilevel
linear models and the GEE to identify which factors
inﬂuence the effectiveness of the disease-speciﬁc CBT.
Multiple imputation will be used to deal with missing
values.
DISCUSSION
PASCET-PI has proven to be effective in reducing depres-
sion in adolescents with IBD. However, the effect on
anxiety, quality of life and disease course has hardly been
studied systematically. We will perform a prospective RCT
to examine the effectiveness of the PASCET-PI on both
symptoms of depression and anxiety, on quality of life,
and on clinical course of the inﬂammatory disease.
This study has several strengths. First, as this study
examines the effect of disease-speciﬁc CBT on both psy-
chological problems and disease course, it will provide
insight to the complex interplay between inﬂammation
and depression or anxiety in paediatric patients. We will
study possible effects of reduction in depression or
anxiety on cytokine expression and RNA expression pro-
ﬁles before and after CBT for subclinical depression or
anxiety. Second, the disease-speciﬁc CBT will target both
depression and anxiety, which is important, as these pro-
blems have a negative impact on medication adherence
and long-term medical and psychological out-
comes.16 19 23 24 29 45–47 Third, this study will provide
important information about the prevalence of depres-
sion and anxiety among adolescents with IBD in an
European country, such as the Netherlands, as com-
pared to other studies that were performed mainly in
the USA. Cultural differences may play a role in coping
with disease-related anxiety and depression. Fourth, the
PASCET-PI encompasses IBD-speciﬁc components,
which matches patients’ IBD-related concerns and pro-
blems very well. If proven effective, the PASCET-PI can
be very helpful for treatment of current and also for pre-
vention of future psychological problems. A ﬁfth
strength of the study is the random and longitudinal
nature of the design. Patients will be randomly assigned
to the experimental or control condition. It is known
that academic hospitals treat more severe IBD cases than
community hospitals. Therefore, the randomisation will
be stratiﬁed for academic versus community hospitals.
Randomised patients will complete several follow-up
assessments, which allows us to evaluate long-term
effects of the PASCET-PI.
In conclusion, there is a compelling need to improve
the emotional well-being of the adolescents with IBD
who suffer from (subclinical) depression or anxiety
symptoms. If the PASCET-PI proves to be effective in
treating both subclinical depression and anxiety, in
improving quality of life, and in preventing clinical
relapse, screening for and treatment of psychological
problems in adolescents with IBD should be incorpo-
rated in standard care.
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